| Literature DB >> 34510859 |
Sukdong Yoo1, Min Hyun Cho2, Hee Sun Baek2, Ji Yeon Song1, Hye Sun Lee3, Eun Mi Yang4, Kee Hwan Yoo5, Su Jin Kim6, Jae Il Shin7, Keum Hwa Lee7, Tae-Sun Ha8, Kyung Mi Jang9, Jung Won Lee10, Kee Hyuck Kim11, Heeyeon Cho12, Mee Jeong Lee13, Jin-Soon Suh14, Kyoung Hee Han15, Hye Sun Hyun16, Il-Soo Ha17, Hae Il Cheong18, Hee Gyung Kang17, Mee Kyung Namgoong19, Hye-Kyung Cho20, Jae-Hyuk Oh21, Sang Taek Lee22, Kyo Sun Kim23, Joo Hoon Lee24, Young Seo Park24, Seong Heon Kim1.
Abstract
BACKGROUND: The clinical features of pediatric rhabdomyolysis differ from those of the adults with rhabdomyolysis; however, multicenter studies are lacking. This study aimed to investigate the characteristics of pediatric rhabdomyolysis and reveal the risk factors for acute kidney injury (AKI) in such cases.Entities:
Keywords: Creatine kinase; Etiology; Muscles; Renal insufficiency
Year: 2021 PMID: 34510859 PMCID: PMC8685356 DOI: 10.23876/j.krcp.21.051
Source DB: PubMed Journal: Kidney Res Clin Pract ISSN: 2211-9132
Figure 1.CONSORT flow diagram.
AKI, acute kidney injury.
Characteristics of patients with acute rhabdomyolysis with or without AKI
| Variable | AKI (n = 99) | Non-AKI (n = 781) | Total (n = 880) | p-value |
|---|---|---|---|---|
| Male sex | 65 (65.7) | 569 (72.9) | 634 (72.0) | 0.17 |
| Age at diagnosis (yr) | 12.2 (6.0–15.1) | 8.0 (4.0–13.4) | 8.0 (4.0–14.0) | <0.001 |
| 0–2 | 12 (12.1) | 140 (17.9) | 152 (17.3) | |
| 3–5 | 11 (11.1) | 160 (20.5) | 171 (19.4) | |
| 6–8 | 9 (9.1) | 119 (15.2) | 128 (14.5) | |
| 9–11 | 11 (11.1) | 86 (11.0) | 97 (11.0) | |
| 12–14 | 22 (22.2) | 142 (18.2) | 164 (18.6) | |
| 15–18 | 34 (34.3) | 134 (17.2) | 168 (19.1) | |
| Height z-score | 0.17 (−1.12 to 1.16) | 0.29 (−0.70 to 1.35) | 0.29 (−0.76 to 1.30) | 0.57 |
| Weight z-score | 0.01 (−1.36 to 0.84) | −0.12 (−1.05 to 0.78) | −0.11 (−1.09 to 0.78) | 0.95 |
| BMI z-score | −0.03 (−1.29 to 0.86) | −0.26 (−1.09 to 0.71) | −0.23 (−1.10 to 0.72) | 0.54 |
| BSA | 1.28 (0.83–1.60) | 0.96 (0.70–1.39) | 0.97 (0.72–1.44) | 0.00 |
| Myalgia or muscle weakness | 41 (41.4) | 301 (38.5) | 342 (38.9) | 0.66 |
| Dark-colored-urine | 20 (20.2) | 103 (13.2) | 123 (14.0) | 0.08 |
| Oliguria, yes | 36 (36.4) | 0 (0) | 36 (4.13) | <0.001 |
| No. of causal factors | 0.07 | |||
| Single | 92 (92.9) | 758 (97.1) | 850 (96.6) | |
| Multiple | 7 (7.1) | 23 (2.9) | 30 (3.4) |
Data are expressed as number (%) or median (interquartile range).
AKI, acute kidney injury; BMI, body mass index; BSA, body surface area.
National database of BMI only includes individuals older than 2 years.
BSA z-score was not available in our study.
Multiple responses allowed the collection of causal factor data.
Figure 2.Underlying diseases of rhabdomyolysis.
(A) Proportion of each underlying disorder. (B) Age distribution of the underlying disorder.
ANP, allergy and pulmonological disorders; CAR, cardiologic disorder; END, endocrinological and metabolic disorders; GAS, genetic and syndromic disorders; NEP, nephrological disorder; NEU, neurological disorder; ONC, oncologic disorder; OD, other disorders; PSY, psychological disorder; UD, underlying disorder.
Figure 3.Cause of rhabdomyolysis.
(A) Proportion of each cause. Infection, including both influenza and other infections, was the most prevalent cause (39.0%). (B) Age distribution of the causes.
AKI, acute kidney injury.
Laboratory results of acute rhabdomyolysis in those with and without AKI
| Variable | AKI (n = 99) | Non-AKI (n = 781) | Total (n = 880) | p-value |
|---|---|---|---|---|
| Urine test | ||||
| Urine occult blood | <0.001 | |||
| Negative | 27 (27.3) | 544 (69.7) | 571 (64.9) | |
| Trace | 0 (0) | 12 (1.5) | 12 (1.4) | |
| 1+ | 9 (9.1) | 54 (6.9) | 63 (7.2) | |
| 2+ | 17 (17.2) | 52 (6.7) | 69 (7.8) | |
| 3+ | 38 (38.4) | 106 (13.6) | 144 (16.4) | |
| 4+ | 8 (8.1) | 13 (1.7) | 21 (2.4) | |
| Urine RBC count (/HPF) | 34 ± 67 | 12 ± 43 | 15 ± 46 | 0.002 |
| True hematuria, RBC ≥ 5/HPF | 45 (45.5) | 105 (13.4) | 150 (17.0) | <0.001 |
| Urine myoglobin, positive (n = 267) | 28 (82.4) | 96 (41.2) | 124 (46.4) | <0.001 |
| Blood test results at initial consult | ||||
| CK (U/L) | 3,161 (1,050−12,772) | 1,986 (1,078−5,698) | 2,144 (1,077−6,262) | 0.05 |
| Myoglobin (mg/mL) | 2,072 (512−6,085) | 2,266 (243−12,449) | 2,159 (278−12,449) | 0.93 |
| AST (U/L) | 179 (78−973) | 86 (49−213) | 90 (50−263) | <0.001 |
| ALT (U/L) | 88 (24−382) | 34 (17−120) | 36 (17−138) | <0.001 |
| LDH (U/L) | 1,264 (756−3,766) | 677 (531−1,152) | 725 (542−1,354) | <0.001 |
| BUN (mg/dL) | 25.4 (15.5−53.5) | 10.8 (8.3−13.5) | 11.2 (8.4−14.7) | <0.001 |
| Creatinine (mg/dL) | 1.5 (0.9−3.0) | 0.5 (0.4−0.7) | 0.5 (0.4−0.8) | <0.001 |
| Uric acid (mg/dL) | 8.0 (5.6−12.5) | 4.2 (3.2−5.9) | 4.5 (3.2−6.3) | <0.001 |
| Calcium (mg/dL) | 8.6 (7.5−9.2) | 9.2 (8.8−9.6) | 9.1 (8.7−9.6) | <0.001 |
| Phosphorus (mg/dL) | 5.1 (4.1−6.5) | 4.4 (3.9−5.1) | 4.5 (3.9−5.2) | <0.001 |
| Peak values recorded during the treatment period | ||||
| CK (U/L) | 6,562 (2,340−21,127) | 2,685 (1,425−7,777) | 2,859 (1,452−9,090) | <0.001 |
| Myoglobin (mg/mL) | 2,724 (694−5,406) | 1,000 (193−4,014) | 1,063 (217−4,030) | 0.001 |
| AST (U/L) | 406 (110−1,933) | 112 (65−318) | 120 (67−397) | <0.001 |
| ALT (U/L) | 244 (50−809) | 49 (26−176) | 53.50 (27−221) | <0.001 |
| LDH (U/L) | 1,982 (872−4,949) | 790 (581−1,516) | 841 (591−1,842) | <0.001 |
| BUN (mg/dL) | 41.7 (21.0−65.5) | 12.1 (9.4−15.2) | 12.7 (9.9−17.0) | <0.001 |
| Creatinine (mg/dL) | 2.2 (1.1−3.7) | 0.5 (0.4−0.7) | 0.6 (0.4−0.8) | <0.001 |
| Uric acid (mg/dL) | 10.9 (6.6−13.7) | 4.8 (3.6−6.1) | 5.1 (3.8−6.6) | <0.001 |
| Calcium (mg/dL) | 9.4 (9.1−10.1) | 9.6 (9.1−10) | 9.5 (9.1−10.0) | 0.57 |
| Phosphorus (mg/dL) | 5.9 (5.1−7.3) | 5 (4.5−5.6) | 5.1 (4.5−5.7) | <0.001 |
Data are expressed as number (%), mean ± standard deviation, or median (interquartile range).
AKI, acute kidney injury; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CK, creatine kinase; HPF, high-power field; LDH, lactate dehydrogenase; RBC, red blood cell.
Multiple logistic regression model for predicting AKI in patients with acute rhabdomyolysis
| Variable | OR (95% CI) | p-value |
|---|---|---|
| Age group (yr) | Reference = 3–5 yr | |
| 0–2 | 0.96 (0.32–2.87) | 0.95 |
| 6–8 | 0.84 (0.24–2.89) | 0.78 |
| 9–12 | 0.72 (0.21–2.44) | 0.59 |
| 12–14 | 1.15 (0.43–3.1) | 0.79 |
| 15–18 | 2.30 (0.89–5.93) | 0.09 |
| Presence of underlying disorder | 3.35 (1.91–5.88) | <0.001 |
| Multiorgan failure | 6.28 (1.92–20.57) | 0.002 |
| Urine occult blood | Reference = negative | |
| Trace | 0 (0–infinity) | >0.99 |
| 1+ | 2.05 (0.78–5.38) | 0.15 |
| 2+ | 2.69 (1.07–6.74) | 0.03 |
| 3+ | 4.46 (2.22–8.97) | <0.001 |
| 4+ | 5.21 (1.53–17.81) | 0.008 |
| CK/100[ | 1 (1.00–1.00) | 0.43 |
| AST/100[ | 1.05 (1.01–1.09) | 0.01 |
| Uric acid | 1.23 (1.14–1.34) | <0.001 |
| Calcium | 0.78 (0.65–0.94) | 0.008 |
| Phosphorus | 1.03 (0.89–1.19) | 0.73 |
Initial creatinine was included in the multivariable logistic regression analysis to reveal uric acid, phosphorous, and calcium as risk factors for AKI, independent of creatinine.
AKI, acute kidney injury; AST, aspartate aminotransferase; CI, confidence interval; CK, creatine kinase; OR, odds ratio.
Laboratory findings at initial consult.
OR of CK/100 and AST/100 can be interpreted as 100-unit increases in the values of CK and AST.
Age range of 3 to 5 years was selected as the reference because this age group had the lowest incidence of AKI.
Figure 4.Receiver-operating characteristic curve of the multiple logistic regression model for predicting acute kidney injury.
Outcomes and complications of acute rhabdomyolysis in patients with or without AKI
| Variable | AKI (n = 99) | Non-AKI (n = 781) | Total (n = 880) | p-value |
|---|---|---|---|---|
| Short-term outcomes | ||||
| CK recovery time (day) | 7.0 (3.5–12.5) | 6.0 (4.0–8.0) | 6.0 (4.0–9.0) | 0.11 |
| Myoglobin recovery time (day) | 5.0 (3.0–11.0) | 5.0 (3.0–9.0) | 5.0 (3.0–9.0) | 0.44 |
| Oliguria recovery time (day) | 2.5 (2.0–8.0) | NA | 2.5 (2.0–8.0) | 0.005 |
| Volume overload, yes (n=529) | 24 (33.8) | 3 (0.7) | 27 (5.1) | <0.001 |
| Duration of hospitalization (day) | 18.0 (7.0–38.0) | 6.0 (4.0–10.0) | 7.0 (4.0–12.0) | <0.001 |
| Long-term outcome (n = 522) | <0.001 | |||
| None | 39 (82.9) | 460 (96.8) | 499 (95.6) | |
| Chronic kidney disease | 3 (6.4) | 0 (0) | 3 (0.6) | |
| Recurrent rhabdomyolysis | 5 (10.5) | 15 (3.2) | 20 (3.8) | |
| Complications | ||||
| None | 10 (10.1) | 734 (94.0) | 744 (84.6) | <0.001 |
| AKI | 99 (100) | 0 (0) | 99 (11.3) | <0.001 |
| Compartment syndrome | 0 (0) | 2 (0.3) | 2 (0.2) | >0.99 |
| DIC | 12 (12.1) | 3 (0.4) | 15 (1.7) | <0.001 |
| Electrolyte disturbance | 25 (25.3) | 29 (3.7) | 54 (6.1) | <0.001 |
| Death | 14 (14.1) | 14 (1.8) | 28 (3.2) | <0.001 |
Data are expressed as median (interquartile range) or number (%).
AKI, acute kidney injury; CK, creatine kinase; DIC, disseminated intravascular coagulation; NA, not applicable.
The number of patients except missing value.
Multiple responses allowed the collection of data on complications.
Figure 5.Distribution of complications by age in rhabdomyolysis patients.
AKI, acute kidney injury; DIC, disseminated intravascular coagulopathy.
Differences in treatment for patients with acute rhabdomyolysis with and without AKI
| Treatment | AKI (n = 99) | Non-AKI (n = 781) | Total (n = 880) | p-value |
|---|---|---|---|---|
| Volume replacement | 74 (74.7) | 560 (71.7) | 634 (72.0) | 0.61 |
| Alkalization | 29 (29.3) | 73 (9.3) | 102 (11.6) | <0.001 |
| Mannitol | 10 (10.1) | 24 (3.1) | 34 (3.9) | 0.003 |
| Dialysis | 31 (31.3) | 0 (0) | 31 (3.5) | <0.001 |
| No specific therapy | 11 (11.1) | 202 (25.9) | 213 (24.2) | 0.002 |
Data are expressed as number (%).
Multiple responses allowed the collection of treatment method data. AKI, acute kidney injury.